行情

CNTX

CNTX

Centrexion Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

0.0000
0.0000
0.00%
停牌
开盘
--
昨收
--
最高
--
最低
--
成交量
--
成交额
--
52周最高
--
52周最低
--
市值
0
市盈率(TTM)
0.0000
分时
5日
1月
3月
1年
5年

CNTX 新闻

  • Uber同意将印度食品配送业务出售给Zomato
  • 新浪财经.3小时前
  • 越南实施史上最严酒驾法 啤酒销量暴跌25%
  • 新浪财经.3小时前
  • 王慧文即将退出,美团增长面临什么挑战?
  • 虎嗅APP.3小时前
  • 去年中国吸收外资1400亿美元 仍是第二大外资流入国
  • 新华社.4小时前

更多

所属板块

制药
+0.13%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CNTX 简况

Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies associated with a wide variety of common disease states. CNTX-4975 is designed to target and disrupt the signaling of pain-sensing nerve fibers. CNTX-0290 product candidate is an investigational small molecule SSTR4 agonist. CNTX-6970 is a potent and selective investigational CCR2 antagonist. CNTX-6970 is a small molecule intended to be administered orally. CNTX-2022 is a proprietary, high concentration topical gel formulation of lidocaine.
展开

Webull提供Centrexion Therapeutics Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。